Robert A. Watson

Oxford, ENG OX12JD, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK.

Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK.

Journal: The Lancet. Oncology

Published: December 25, 2025

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Journal: Nature medicine

Published: December 23, 2024

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2024

Guest Editorial: Focusing on What Matters Most-Impact.

Guest Editorial: Focusing on What Matters Most-Impact.

Journal: Environmental health perspectives

Published: September 21, 2023

Reduction in Chest CT Severity and Improved Hospital Outcomes in SARS-CoV-2 Omicron Compared with Delta Variant Infection.

Reduction in Chest CT Severity and Improved Hospital Outcomes in SARS-CoV-2 Omicron Compared with Delta Variant Infection.

Journal: Radiology

Published: June 21, 2022

IFNγ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells.

IFNγ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells.

Journal: Nature communications

Published: May 29, 2022

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Journal: Nature medicine

Published: April 06, 2022

Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity.

Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity.

Journal: Science immunology

Published: October 01, 2021

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.

Journal: Nature immunology

Published: July 19, 2021

Natural Killer cells demonstrate distinct eQTL and transcriptome-wide disease associations, highlighting their role in autoimmunity.

Natural Killer cells demonstrate distinct eQTL and transcriptome-wide disease associations, highlighting their role in autoimmunity.

Journal: Nature communications

Published: May 11, 2021

Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.

Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.

Journal: British journal of cancer

Published: December 14, 2020

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

Journal: Nature medicine

Published: October 29, 2019

Showing 1-12 of 22

Last Updated: 09/26/2026